Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 2
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
Capasso N, Nozzolillo A, Scalia G, Lanzillo R, Carotenuto A, De Angelis M, Petruzzo M, Saccà F, Russo CV, Brescia Morra V, Moccia M. Capasso N, et al. Mult Scler Relat Disord. 2021 Apr;49:102802. doi: 10.1016/j.msard.2021.102802. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33556652
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis.
Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, Petracca M, Novarella F, Covelli B, Scalia G, Brescia Morra V, Moccia M. Spiezia AL, et al. Among authors: capasso n. Mult Scler Relat Disord. 2022 Jan;57:103431. doi: 10.1016/j.msard.2021.103431. Epub 2021 Nov 29. Mult Scler Relat Disord. 2022. PMID: 34871857 No abstract available.
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis.
Novarella F, Carotenuto A, Cipullo P, Iodice R, Cassano E, Spiezia AL, Capasso N, Petracca M, Falco F, Iacovazzo C, Servillo G, Lanzillo R, Brescia Morra V, Moccia M. Novarella F, et al. Among authors: capasso n. Toxins (Basel). 2022 Nov 9;14(11):774. doi: 10.3390/toxins14110774. Toxins (Basel). 2022. PMID: 36356024 Free PMC article.
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study.
Lanzillo R, Carotenuto A, Signoriello E, Iodice R, Miele G, Bisecco A, Maniscalco GT, Sinisi L, Romano F, Di Gregorio M, Lavorgna L, Trojsi F, Moccia M, Fratta M, Capasso N, Dubbioso R, Petracca M, Spiezia AL, Gallo A, Petruzzo M, De Angelis M, Bonavita S, Lus G, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Among authors: capasso n. J Clin Med. 2022 Apr 7;11(8):2081. doi: 10.3390/jcm11082081. J Clin Med. 2022. PMID: 35456175 Free PMC article.
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg.
Capasso N, Palladino R, Montella E, Pennino F, Lanzillo R, Carotenuto A, Petracca M, Iodice R, Iovino A, Aruta F, Pastore V, Buonomo AR, Zappulo E, Gentile I, Triassi M, Brescia Morra V, Moccia M. Capasso N, et al. J Clin Med. 2020 Dec 16;9(12):4066. doi: 10.3390/jcm9124066. J Clin Med. 2020. PMID: 33339402 Free PMC article.